China NMPA accepts I-MAB drug for trial in pediatric patients

I-MAB, a Shanghai-based clinical stage biopharmaceutical company with its United States base in Gaithersburg, Tuesday the China National Medical Products Administration (NMPA) has accepted its pivotal trial application for eftansomatropin (also known as TJ101) as a weekly treatment for growth hormone deficiency in pediatric patients (PGHD). Eftansomatropin is an innovative long-acting recombinant human growth hormone (rhGH) ...

To purchase a reprint of this article, contact reprints@thedailyrecord.com.

Leave a Reply

Your email address will not be published. Required fields are marked *